Jingjin Li
Impact in
- Genetics top 1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Family Practice top 2%
Papers in
- Oncology 16
- CAR-T cell therapy research 8
- Cancer Immunotherapy and Biomarkers 7
- Co-authors
- Jean‐Jacques Kiladjian (12 shared papers)Srđan Verstovšek (12 shared papers)Mark M. Jones (10 shared papers)Alessandro M. Vannucchi (11 shared papers)Tamás Masszi (9 shared papers)Francesco Passamonti (7 shared papers)Martin Grießhammer (8 shared papers)Simon Durrant (7 shared papers)
- Journals
- Blood (12 papers)Journal of Clinical Oncology (8 papers)Advanced Materials (2 papers)BMC Biology (2 papers)HemaSphere (2 papers)
- Partner nations
- ChinaUnited StatesFrance
In The Last Decade
Jingjin Li
82 papers receiving 2.1k citations
Jingjin Li's Hit Papers
Peers
Comparison fields: 5 of 123
- Genetics 607
- Family Practice 79
- Hematology 432
- Rheumatology 248
- Oncology 356
Countries citing papers authored by Jingjin Li
This map shows the geographic impact of Jingjin Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingjin Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingjin Li more than expected).
Fields of papers citing papers by Jingjin Li
This network shows the impact of papers produced by Jingjin Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingjin Li. The network helps show where Jingjin Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Jingjin Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 87 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera Hit paper breakdown → | 2015 | 611 |
| 2 | 2006 | 128 | |
| 3 | 2012 | 97 | |
| 4 | 2021 | 95 | |
| 5 | 2020 | 89 | |
| 6 | 2011 | 69 | |
| 7 | 2017 | 65 | |
| 8 | 2014 | 61 | |
| 9 | 2013 | 56 | |
| 10 | 2020 | 51 | |
| 11 | 2019 | 50 | |
| 12 | 2021 | 47 | |
| 13 | 2017 | 44 | |
| 14 | 2015 | 39 | |
| 15 | 2005 | 36 | |
| 16 | 2019 | 31 | |
| 17 | 2017 | 27 | |
| 18 | 2022 | 26 | |
| 19 | 2022 | 24 | |
| 20 | 2019 | 23 |
About Jingjin Li
Jingjin Li is a scholar working on Molecular Biology, Oncology, Genetics, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 87 papers that have together received 2.2k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers), CAR-T cell therapy research (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Cancer Immunotherapy and Biomarkers (7 papers), Hemoglobinopathies and Related Disorders (5 papers), Acute Myeloid Leukemia Research (5 papers), MicroRNA in disease regulation (5 papers) and Genetic and phenotypic traits in livestock (4 papers). The work is most often cited by research in Genetics (607 citations), Family Practice (79 citations), Hematology (432 citations), Rheumatology (248 citations) and Oncology (356 citations). Jingjin Li has collaborated with scholars based in China, United States and France. Frequent co-authors include Jean‐Jacques Kiladjian, Srđan Verstovšek, Mark M. Jones, Alessandro M. Vannucchi, Tamás Masszi, Francesco Passamonti, Martin Grießhammer, Simon Durrant, Fabrizio Pane and Ruben A. Mesa. Their work appears in journals such as Blood, Journal of Clinical Oncology, Advanced Materials, BMC Biology and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.